Details of the Drug
General Information of Drug (ID: DMCGRV7)
Drug Name |
1,2-Bis-(4-methoxy-phenyl)-ethane-1,2-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4,4'-Dimethoxybenzil; 1226-42-2; p-Anisil; Anisil; 1,2-bis(4-methoxyphenyl)ethane-1,2-dione; Bis(4-methoxyphenyl)ethanedione; Ethanedione, bis(4-methoxyphenyl)-; Di-p-anisoyl; p,p'-Dimethoxybenzil; 1,2-ethanedione, 1,2-bis(4-methoxyphenyl)-; YNANGXWUZWWFKX-UHFFFAOYSA-N; MFCD00008405; 1,2-Bis(4-methoxyphenyl)-1,2-ethanedione; 1,2-bis(4-methoxyphenyl)-ethane-1,2-dione; AE-641/01115007; W-108428; 4,4'-Dimethoxybenzil, 99+%; EINECS 214-960-5; NSC 19218; ACMC-1BZIL; p-Anisil; Di-p-anisoyl; 4,4\'-Dimethoxybenzil
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure |
![]() |
||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 270.28 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||